Palatin Technologies (PTN) Stock Price, Quote & News

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequatel...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 495 2200

Website: palatin.com

Address:

11 Deer Park Drive, Suite 204, Monmouth Junction, United States

Rollercoaster22 Mar. 17 at 6:18 AM

$PTN 🥳🥳🥳🥳

0 · Reply

Rollercoaster22 Mar. 16 at 10:29 AM

$PTN This is very impressive. The institutions believe in PTN.

0 · Reply

DarkWatcher Mar. 14 at 7:27 AM

$PTN 😂🤣😂 this is like when the magician calls you Down from the audience Yeah!!! I’m the lucky person that got picked! 😂🤣😂

0 · Reply

DarkWatcher Mar. 4 at 5:54 PM

$AITX $CYBL $PTN 🤣

0 · Reply

DarkWatcher Mar. 3 at 6:07 AM

$AITX $PTN $IQST 😉🤣😂🤣🤘

1 · Reply

DarkWatcher Feb. 25 at 12:52 PM

$PTN break these damn shorts until they drop every dollar! 😂

0 · Reply

JOHNB21400 Feb. 24 at 7:12 PM

$PTN Twenty three and me moving up.

1 · Reply

DarkWatcher Feb. 23 at 5:27 PM

$PTN

0 · Reply

Stocks787 Feb. 23 at 11:56 AM

$PTN Novo Nordisk NVO ▼2.13% shares fell nearly 13% in pre-market trading today after the company said its next obesity drug did not match Eli Lilly LLY ▼1.34% in a head-to-head trial. The update marks a key moment in the fast-growing weight loss drug race, where even small gaps in results can shift market share and investor trust.

0 · Reply

RadPoppa Feb. 21 at 1:41 AM

$PTN I lost 3k on this before so was skittish on getting back in especially with a delisting but now I’m getting fomo… thinking about it now.

1 · Reply

Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline ...

2026-02-17T23:00:29.000Z - 4 weeks ago

Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...

2026-02-17T21:00:19.000Z - 4 weeks ago

Q2 2026 Palatin Technologies Inc Earnings Call Transcript

Tue, 17 Feb 2026 13:34:55 -0500 - 4 weeks ago

Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript

Tue, 17 Feb 2026 07:30:00 -0500 - 4 weeks ago

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

2026-01-12T15:30:03.000Z - 2 months ago

Palatin Technologies Targets Hypothalamic Obesity as Next Frontier Beyond GLP-1s (NYSE: PTN)

2025-12-13T00:38:01.000Z - 3 months ago

JANUS HENDERSON GROUP PLC Acquires Shares in Palatin Technologies Inc

2025-12-11T07:20:11.000Z - 3 months ago

Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?

2025-11-13T23:01:11.000Z - 4 months ago

Palatin Technologies Inc (PTN) Q1 2026 Earnings Call Highlights: Strategic Collaborations and ...

2025-11-13T21:16:07.000Z - 4 months ago

Q1 2026 Palatin Technologies Inc Earnings Call Transcript

Thu, 13 Nov 2025 15:41:39 -0500 - 4 months ago

Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript

Thu, 13 Nov 2025 07:30:00 -0500 - 4 months ago

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Wed, 12 Nov 2025 12:15:00 -0500 - 4 months ago

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Nov 6, 2025, 8:00 AM EST - 4 months ago

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

Nov 6, 2025, 7:30 AM EST - 4 months ago

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

Sep 22, 2025, 7:30 AM EDT - 6 months ago

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

Aug 18, 2025, 8:05 AM EDT - 7 months ago

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Aug 8, 2025, 4:00 PM EDT - 7 months ago

Palatin Announces 1-for-50 Reverse Stock Split

Jul 15, 2025, 7:30 AM EDT - 8 months ago

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

Wed, 14 May 2025 07:30:00 -0400 - 11 months ago

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

May 9, 2025, 7:30 AM EDT - 11 months ago

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

May 8, 2025, 10:19 PM EDT - 11 months ago

Palatin Technologies Announces Closing of Reduced Public Offering

Wed, 07 May 2025 20:26:00 -0400 - 11 months ago

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

Wed, 07 May 2025 17:20:00 -0400 - 11 months ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

Wed, 07 May 2025 08:15:00 -0400 - 11 months ago

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

Wed, 07 May 2025 08:00:00 -0400 - 11 months ago

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

2025-05-07T12:00:00.000Z - 11 months ago

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

Mon, 05 May 2025 07:30:00 -0400 - 11 months ago

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Tue, 29 Apr 2025 07:30:00 -0400 - 11 months ago

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Thu, 17 Apr 2025 07:30:00 -0400 - 11 months ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Mon, 14 Apr 2025 07:00:00 -0400 - 1 year ago

Palatin Appeals NYSE American Notice of Delisting

Thu, 10 Apr 2025 16:15:00 -0400 - 1 year ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

Thu, 10 Apr 2025 16:01:00 -0400 - 1 year ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Thu, 10 Apr 2025 07:30:00 -0400 - 1 year ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Mon, 31 Mar 2025 07:30:00 -0400 - 1 year ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Fri, 28 Mar 2025 07:30:00 -0400 - 1 year ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Tue, 25 Mar 2025 07:30:00 -0400 - 1 year ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

2025-02-15T10:48:51.000Z - 1 year ago

ARMISTICE CAPITAL, LLC Acquires Significant Stake in Palatin Technologies Inc

Sat, 15 Feb 2025 05:41:35 -0500 - 1 year ago

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Thu, 13 Feb 2025 07:30:00 -0500 - 1 year ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Mon, 10 Feb 2025 16:00:00 -0500 - 1 year ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Fri, 07 Feb 2025 08:00:00 -0500 - 1 year ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Thu, 06 Feb 2025 07:30:00 -0500 - 1 year ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Jan 28, 2025, 7:30 AM EST - 1 year ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Dec 19, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Dec 16, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Nov 25, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Thu, 14 Nov 2024 12:49:02 -0500 - 1 year ago

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Nov 14, 2024, 7:30 AM EST - 1 year ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Nov 8, 2024, 9:57 AM EST - 1 year ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Nov 4, 2024, 7:30 AM EST - 1 year ago

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Oct 7, 2024, 4:15 PM EDT - 1 year ago

Palatin Receives Notice of Non-Compliance from NYSE American

Oct 1, 2024, 2:55 PM EDT - 1 year ago

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Aug 28, 2024, 7:30 AM EDT - 1 year ago

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Aug 22, 2024, 7:30 AM EDT - 1 year ago

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Jun 20, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

Jun 12, 2024, 7:30 AM EDT - 1 year ago

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

May 15, 2024, 7:30 AM EDT - 2 years ago

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:30 AM EDT - 2 years ago

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

May 2, 2024, 7:30 AM EDT - 2 years ago

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024

$Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024$

Apr 8, 2024, 7:30 AM EDT - 2 years ago

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Rollercoaster22 Mar. 17 at 6:18 AM

$PTN 🥳🥳🥳🥳

0 · Reply

Rollercoaster22 Mar. 16 at 10:29 AM

$PTN This is very impressive. The institutions believe in PTN.

0 · Reply

DarkWatcher Mar. 14 at 7:27 AM

$PTN 😂🤣😂 this is like when the magician calls you Down from the audience Yeah!!! I’m the lucky person that got picked! 😂🤣😂

0 · Reply

DarkWatcher Mar. 4 at 5:54 PM

$AITX $CYBL $PTN 🤣

0 · Reply

DarkWatcher Mar. 3 at 6:07 AM

$AITX $PTN $IQST 😉🤣😂🤣🤘

1 · Reply

DarkWatcher Feb. 25 at 12:52 PM

$PTN break these damn shorts until they drop every dollar! 😂

0 · Reply

JOHNB21400 Feb. 24 at 7:12 PM

$PTN Twenty three and me moving up.

1 · Reply

DarkWatcher Feb. 23 at 5:27 PM

$PTN

0 · Reply

Stocks787 Feb. 23 at 11:56 AM

0 · Reply

RadPoppa Feb. 21 at 1:41 AM

$PTN I lost 3k on this before so was skittish on getting back in especially with a delisting but now I’m getting fomo… thinking about it now.

1 · Reply

Rollercoaster22 Feb. 20 at 9:47 PM

$PTN Daily. 😁

0 · Reply

Rollercoaster22 Feb. 20 at 9:46 PM

$PTN $50 to begin with. 🤩

0 · Reply

JOHNB21400 Feb. 20 at 5:28 PM

$PTN We are moving in the right direction. Target 50 bucks.

0 · Reply

kc444 Feb. 20 at 2:05 PM

$PTN

0 · Reply

Rollercoaster22 Feb. 20 at 7:44 AM

$PTN

0 · Reply

JOHNB21400 Feb. 19 at 4:18 AM

$PTN Well we finally got a BULLISH indicator from this board. We didn’t hit the target for forty days. Maybe now is the time to succeed all expectations.

0 · Reply

SportTrade Feb. 18 at 8:13 PM

$PTN see 13F public filings for who’s who dedicated HC funds that filed ownership. Perceptive, RA Capital, Driehaus, Janus, Logos, PT72, etc…. These are some of smartest minds in biotech that have clearly done diligence and invested for huge potential upside here. WOW.

1 · Reply

WallStWireAds Feb. 18 at 3:03 PM

$PTN $RYTM Palatin Technologies’ Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline >> https://www.tipranks.com/news/newswire/palatin-technologies-rare-obesity-strategy-sets-up-a-catalyst-rich-2026-for-its-mc4r-pipeline-nyse-ptn

0 · Reply

Rollercoaster22 Feb. 18 at 2:47 PM

$PTN

0 · Reply

DarkWatcher Feb. 18 at 6:10 AM

$PTN $55 dollars per share!!! Hopefully those annals are right 😁

0 · Reply

StocktwitsEarnings Feb. 17 at 2:00 PM

$PTN Q2 '26 Earnings Results & Recap Palatin Technologies expects a cash runway beyond March 31, 2027, with PL7737 IND submission and trial initiation planned for H1 2026. Next-generation MC4R agonists target H2 2026 for IND submission and trial initiation.

0 · Reply

CapitalTrajectory Feb. 17 at 1:03 PM

$PTN Pre-revenue biotech; early-stage.

0 · Reply

Market Cap	2.45M
Revenue (ttm)	4.49M
Net Income (ttm)	-29.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-662.36%
Debt to Equity Ratio	0.00

Volume	14,571,800
Avg Vol	3,131,146
Day's Range	N/A - N/A
Shares Out	26.01M
Stochastic %K	5%
Beta	0.94
Analysts	Strong Sell
Price Target	$7.00